Brian G. Atwood - 31 Mar 2025 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Role
Director
Signature
/s/ Brian G. Atwood
Issuer symbol
CERO
Transactions as of
31 Mar 2025
Net transactions value
+$58.89
Form type
4
Filing time
04 Apr 2025, 19:12:50 UTC
Previous filing
06 Mar 2025
Next filing
02 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERO Common Stock Options Exercise $29.45 +294,460 +150% $0.000100 490,534 31 Mar 2025 See Footnote F1
holding CERO Common Stock 1,250 31 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERO Pre-Funded Warrant Options Exercise $29.45 +294,460 $0.000100 11,660 31 Mar 2025 Common Stock 294,460 $0.000100 Direct F2
holding CERO Pre-Funded Warrant 204,080 31 Mar 2025 Common Stock 204,080 $0.000100 By GVN, LLC F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 28, 2025, Mr. Atwood exercised Pre-Funded Warrants (the "Pre-Funded Warrants") and directed the issuance of the shares of common stock of CERo Therapeutics Holdings, Inc. (the "Issuer") to the Atwood-Edminster Trust dtd 4-2-2000 (the "Trust"). Mr. Atwood and his wife are the managers of the LLC and the trustees of the Trust. Accordingly, Mr. Atwood may be deemed to have beneficial ownership of the securities held directly by the LLC..
F2 The Pre-Funded Warrants are exercisable at any time on or after the date of issuance for an exercise price of $0.0001 per share, for shares of common stock of the Issuer.
F3 GVN, LLC (the "LLC") is a limited liability company of which the sole member is the Trust..